Colbar R&D Ltd.
This article was originally published in Start Up
Israeli-based Colbar R&D ltd has a technology that offers a more durable scaffold for tissue engineering. The technology allows for the first time the precise programming of the collagen matrix that is used in tissue repair. The three year old company has a dental product for tooth implantation on the market in the US and a second product for correcting contour deficiencies in clinical trials in Europe.
You may also be interested in...
Lilly announced it signed strategic international agreements with four diabetes companies to advance connected solutions and streamline care for people with diabetes in markets outside of the US.
Three firms launched initial public offerings during the first week of May, but Gyroscope postponed its IPO while Jasper, Science 37 and Roivant took the special purpose acquisition corporation route.
The partnership helps close the gap between Nkarta and Fate Therapeutics in terms of the breadth of their pipelines.